BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 24912477)

  • 1. Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex.
    Jia D; Dong R; Jing Y; Xu D; Wang Q; Chen L; Li Q; Huang Y; Zhang Y; Zhang Z; Liu L; Zheng S; Xia Q; Wang H; Dong K; He X
    Hepatology; 2014 Nov; 60(5):1686-96. PubMed ID: 24912477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational landscape of hepatoblastoma goes beyond the Wnt-β-catenin pathway.
    Han ZG
    Hepatology; 2014 Nov; 60(5):1476-8. PubMed ID: 25078725
    [No Abstract]   [Full Text] [Related]  

  • 3. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
    Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
    Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.
    Regel I; Eichenmüller M; Mahajan UM; Hagl B; Benitz S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
    J Cancer Res Clin Oncol; 2020 May; 146(5):1153-1167. PubMed ID: 32189106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel tissue-based ß-catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors.
    Dubbink HJ; Hollink IHIM; Avenca Valente C; Wang W; Liu P; Doukas M; van Noesel MM; Dinjens WNM; Wagner A; Smits R
    Pediatr Blood Cancer; 2018 Jun; 65(6):e26991. PubMed ID: 29446530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
    Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
    J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
    Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors.
    Yamaoka H; Ohtsu K; Sueda T; Yokoyama T; Hiyama E
    Oncol Rep; 2006 Mar; 15(3):551-6. PubMed ID: 16465411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGFβ signaling.
    Matsumoto S; Yamamichi T; Shinzawa K; Kasahara Y; Nojima S; Kodama T; Obika S; Takehara T; Morii E; Okuyama H; Kikuchi A
    Nat Commun; 2019 Aug; 10(1):3882. PubMed ID: 31462641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.
    Wei Y; Fabre M; Branchereau S; Gauthier F; Perilongo G; Buendia MA
    Oncogene; 2000 Jan; 19(4):498-504. PubMed ID: 10698519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma.
    Jeng YM; Wu MZ; Mao TL; Chang MH; Hsu HC
    Cancer Lett; 2000 Apr; 152(1):45-51. PubMed ID: 10754205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.
    Koch A; Weber N; Waha A; Hartmann W; Denkhaus D; Behrens J; Birchmeier W; von Schweinitz D; Pietsch T
    J Pathol; 2004 Dec; 204(5):546-54. PubMed ID: 15538750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
    Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice.
    Zhang W; Meyfeldt J; Wang H; Kulkarni S; Lu J; Mandel JA; Marburger B; Liu Y; Gorka JE; Ranganathan S; Prochownik EV
    J Biol Chem; 2019 Nov; 294(46):17524-17542. PubMed ID: 31597698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1.
    Canal F; Anthony E; Lescure A; Del Nery E; Camonis J; Perez F; Ragazzon B; Perret C
    BMC Cancer; 2015 Dec; 15():1020. PubMed ID: 26715116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S119N Mutation of the E3 Ubiquitin Ligase SPOP Suppresses SLC7A1 Degradation to Regulate Hepatoblastoma Progression.
    He W; Zhang J; Liu B; Liu X; Liu G; Xie L; He J; Wei M; Li K; Ma J; Dong R; Ma D; Dong K; Ye M
    Mol Ther Oncolytics; 2020 Dec; 19():149-162. PubMed ID: 33209975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HGF/c-Met related activation of β-catenin in hepatoblastoma.
    Purcell R; Childs M; Maibach R; Miles C; Turner C; Zimmermann A; Sullivan M
    J Exp Clin Cancer Res; 2011 Oct; 30(1):96. PubMed ID: 21992464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
    Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
    J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.
    Juhlin CC; Goh G; Healy JM; Fonseca AL; Scholl UI; Stenman A; Kunstman JW; Brown TC; Overton JD; Mane SM; Nelson-Williams C; Bäckdahl M; Suttorp AC; Haase M; Choi M; Schlessinger J; Rimm DL; Höög A; Prasad ML; Korah R; Larsson C; Lifton RP; Carling T
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E493-502. PubMed ID: 25490274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma.
    Iolascon A; Giordani L; Moretti A; Basso G; Borriello A; Della Ragione F
    Hepatology; 1998 Apr; 27(4):989-95. PubMed ID: 9537438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.